GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomics Biopharma Ltd (ASX:BBM) » Definitions » Short-Term Capital Lease Obligation

Biomics Biopharma (ASX:BBM) Short-Term Capital Lease Obligation : A$0.00 Mil (As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Biomics Biopharma Short-Term Capital Lease Obligation?

Biomics Biopharma's Short-Term Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil.


Biomics Biopharma Short-Term Capital Lease Obligation Historical Data

The historical data trend for Biomics Biopharma's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomics Biopharma Short-Term Capital Lease Obligation Chart

Biomics Biopharma Annual Data
Trend
Short-Term Capital Lease Obligation

Biomics Biopharma Semi-Annual Data
Short-Term Capital Lease Obligation

Biomics Biopharma Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


Biomics Biopharma Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Biomics Biopharma's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomics Biopharma (ASX:BBM) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.

Biomics Biopharma (ASX:BBM) Headlines

No Headlines